arrow
S

Sanne de Bruin

Amsterdam University Medical Center
H指数:27
被引数:9,991

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transfusion intensity in the ICU: Reasons and triggers

ICU中的输血强度:原因和触发因素

2026-09-300
OAAI
Association between red blood cell transfusion and adverse clinical outcomes is Independent of cardiac history: a multicenter observational InPUT study analysis

红细胞输注与不良临床结局之间的关联与心脏病史无关:一项多中心观察性InPUT研究的分析

2025-12-180
OAAI
Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unit

多国输血实践与入住重症监护病房的血液病患者的结局

2025-11-010
OAAI
Global transfusion practices in septic patients in the intensive care unit: insights from the InPUT-study sub-analysis

重症监护病房脓毒症患者的全球输血实践:InPUT-study子分析的见解

2025-10-220
OAAI
Post-transfusion recovery, quality and metabolism of short and long-term stored platelets during controlled inflammation

输血后恢复、短期和长期储存血小板的品质及代谢在可控炎症期间的变化

2025-07-280
OAAI
Hemostatic conditions following autologous transfusion of fresh vs stored platelets in experimental endotoxemia: an open-label randomized controlled trial with healthy volunteers
2024-11-010
OAAI
Red Blood Cell Transfusion in the Intensive Care Unit

重症监护病房的红细胞输注

2023-11-2116
OA
Vilobelimab's effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
2023-10-270
PRE
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Anti-C5a抗体 (vilobelimab) 治疗重症,侵入性机械通气新型冠状病毒肺炎患者 (PANAMO): 一项多中心,双盲,随机,安慰剂对照的3期试验

2022-12-0172
OAAI
Transfusion strategies in bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine
2021-10-2244
OAAI
Clinical features and prognostic factors in Covid-19: A prospective cohort study
2021-05-0173
OAAI
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
2020-12-1562
OAAI
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
2020-12-01141
OAAI
Y-RNA subtype ratios in plasma extracellular vesicles are cell type-specific and are candidate biomarkers for inflammatory diseases
2020-05-2632
OAAI